ErbB family receptor (ErbB)

The ErbB family receptor refers collectively to four highly homologous receptor tyrosine kinases: EGFR (ErbB1/HER1), HER2 (ErbB2), HER3 (ErbB3), and HER4 (ErbB4)[1][7]. These transmembrane proteins mediate the cellular effects of epidermal growth factor-like ligands through homo- and heterodimerization, leading to activation of intracellular kinase domains and downstream signaling cascades such as PI3K/Akt, JAK/STAT, and MAPK pathways[3][4][5]. ErbB receptor signaling regulates proliferation, differentiation, migration, and survival; disruption, overexpression, or mutation of ErbB receptors is implicated in numerous cancers and developmental disorders[1][4]. Targeting ErbB signaling, via small molecule kinase inhibitors or monoclonal antibodies, forms the basis of many approved therapies in oncology[4][7]. Individual family members have unique ligand-binding profiles, dimerization preferences, and roles in physiology and pathogenesis[1][3][5].

Other names

Epidermal growth factor receptor familyErbB receptorsHER familyEGFR familyIndividual aliases: EGFR (ErbB1/HER1)HER2/neu (ErbB2)HER3 (ErbB3)HER4 (ErbB4)

Inhibition of tyrosine kinase activity (ATP-competitive binding at the kinase domain); Antibody-mediated blockade of extracellular ligand binding or dimerization; Irreversible binding to the receptor or covalent modification (for some kinase inhibitors); Promotion of receptor degradation